We have located links that may give you full text access.
Role of subintimal angioplasty in the treatment of chronic lower limb ischaemia.
European Journal of Vascular and Endovascular Surgery 2002 November
OBJECTIVES: To determine the clinical outcome of subintimal angioplasty (SA) and to assess impact on surgical workload.
DESIGN: Retrospective review of a single radiologist's case series.
MATERIALS: One hundred and twenty two patients with critical limb ischaemia and 26 with claudication.
METHODS: One hundred and fifty eight limbs treated by SA.
MAIN OUTCOME MEASURES: Technical success and complications; cumulative patency, limb salvage and survival; affect of SA on vascular workload.
RESULTS: The technical success rate was 85%. There were 26 procedural complications (16%) but no patient required emergency surgery; 30-day mortality was 3%. Primary and secondary 12-month patency rates were 27 and 33%. Limb salvage rate was 88% at 12 months. SA initially reduced the number of patients needing arterial surgery, although this then increased due to late failure of SA and an increase in de novo bypass.
CONCLUSIONS: SA carries a low risk of major complications and high immediate technical success. Poor long-term patency suggests that SA is not as durable as bypass surgery. However, failed SA did not compromise subsequent surgery, which only became necessary in a proportion of patients. Our data suggests that there is little to be lost by using SA as first-line treatment for patients with limb-threatening ischaemia who are poor operative risks or who have no autologous vein available.
DESIGN: Retrospective review of a single radiologist's case series.
MATERIALS: One hundred and twenty two patients with critical limb ischaemia and 26 with claudication.
METHODS: One hundred and fifty eight limbs treated by SA.
MAIN OUTCOME MEASURES: Technical success and complications; cumulative patency, limb salvage and survival; affect of SA on vascular workload.
RESULTS: The technical success rate was 85%. There were 26 procedural complications (16%) but no patient required emergency surgery; 30-day mortality was 3%. Primary and secondary 12-month patency rates were 27 and 33%. Limb salvage rate was 88% at 12 months. SA initially reduced the number of patients needing arterial surgery, although this then increased due to late failure of SA and an increase in de novo bypass.
CONCLUSIONS: SA carries a low risk of major complications and high immediate technical success. Poor long-term patency suggests that SA is not as durable as bypass surgery. However, failed SA did not compromise subsequent surgery, which only became necessary in a proportion of patients. Our data suggests that there is little to be lost by using SA as first-line treatment for patients with limb-threatening ischaemia who are poor operative risks or who have no autologous vein available.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app